Model-observational bridging study on the effectiveness of ezetimibe on cardiovascular morbidity and mortality in France: A population-based study

Nichols, 2012 Lewington, 2007, Blood cholesterol and vascular mortality by age, sex, and blood pressure: a meta-analysis of individual data from 61 prospective studies with 55,000 vascular deaths, Lancet, 370, 1829, 10.1016/S0140-6736(07)61778-4 Taylor, 2013, Statins for the primary prevention of cardiovascular disease, Cochrane Database Syst Rev, 1, CD004816 Fulcher, 2015, Efficacy and safety of LDL-lowering therapy among men and women: meta-analysis of individual data from 174,000 participants in 27 randomised trials, Lancet, 385, 1397, 10.1016/S0140-6736(14)61368-4 Perk, 2012, Atherosclerosis, 223, 1, 10.1016/j.atherosclerosis.2012.05.007 2009 Grimaldi-Bensouda, 2010, Agreement between patients' self-report and physicians' prescriptions on cardiovascular drug exposure: the PGRx database experience, Pharmacoepidemiol Drug Saf, 19, 591, 10.1002/pds.2055 Vergnaud, 2008, Ten-year risk prediction in French men using the Framingham coronary score: results from the national SU.VI.MAX cohort, Prev Med, 47, 61, 10.1016/j.ypmed.2008.02.023 2005, 65 2012 Caro, 2010, Discrete event simulation: the preferred technique for health economic evaluations?, Value Health, 13, 1056, 10.1111/j.1524-4733.2010.00775.x Denke, 2006, Ezetimibe added to ongoing statin therapy improves LDL-C goal attainment and lipid profile in patients with diabetes or metabolic syndrome, Diab Vasc Dis Res, 3, 93, 10.3132/dvdr.2006.020 Pearson, 2006, Mayo Clin Proc, 81, 1177, 10.4065/81.9.1177 Norata, 2013, New therapeutic principles in dyslipidaemia: focus on LDL and Lp(a) lowering drugs, Eur Heart J, 34, 1783, 10.1093/eurheartj/eht088 Anderson, 1991, Cardiovascular disease risk profiles, Am Heart J, 121, 293, 10.1016/0002-8703(91)90861-B D'Agostino, 2000, Primary and subsequent coronary risk appraisal: new results from the Framingham study, Am Heart J, 139, 272, 10.1016/S0002-8703(00)90236-9 Gudzune, 2014, Effectiveness of combination therapy with statin and another lipid-modifying agent compared with intensified statin monotherapy: a systematic review, Ann Intern Med, 160, 468, 10.7326/M13-2526 Mikhailidis, 2011, Comparative efficacy of the addition of ezetimibe to statin vs statin titration in patients with hypercholesterolaemia: systematic review and meta-analysis, Curr Med Res Opin, 27, 1191, 10.1185/03007995.2011.571239 Savarese, 2015, Safety and efficacy of ezetimibe: A meta-analysis, Int J Cardiol, 201, 247, 10.1016/j.ijcard.2015.08.103 Battaggia, 2015, Clinical efficacy and safety of Ezetimibe on major cardiovascular endpoints: systematic review and meta-analysis of randomized controlled trials, PLoS One, 10, e0124587, 10.1371/journal.pone.0124587 Cannon, 2015, Ezetimibe added to statin therapy after acute coronary syndromes, N Engl J Med, 372, 2387, 10.1056/NEJMoa1410489 2006 Danaei, 2012, Bias in observational studies of prevalent users: lessons for comparative effectiveness research from a meta-analysis of statins, Am J Epidemiol, 175, 250, 10.1093/aje/kwr301 Caro, 2004, Comparing medications in a therapeutic area using an NNT model, Value Health, 7, 585, 10.1111/j.1524-4733.2004.75009.x 2012 Suissa, 2015, The Number Needed to Treat: 25 Years of Trials and Tribulations in Clinical Research, Rambam Maimonides Med J, 6, 42, 10.5041/RMMJ.10218